These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37236494)

  • 1. Distribution, metabolism, and toxicity of antimony species in wistar rats. A bio-analytical approach.
    Ogra Y; Roldán N; Verdugo M; Gonzalez AA; Suzuki N; Quiroz W
    Environ Toxicol Pharmacol; 2023 Jun; 100():104160. PubMed ID: 37236494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
    de Moura FJ; Leal PP; de Souza Furtado R; Muniz-Junqueira MI; Veiga JP
    Toxicology; 2008 Jan; 243(1-2):66-74. PubMed ID: 18022309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.
    Frézard F; Demicheli C; Ferreira CS; Costa MA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):913-6. PubMed ID: 11181379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.
    Coelho DR; Miranda ES; Saint'Pierre TD; Paumgartten FJ
    Mem Inst Oswaldo Cruz; 2014 Jul; 109(4):420-7. PubMed ID: 25075781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimony oxidation states in antileishmanial drugs.
    Franco MA; Barbosa AC; Rath S; Dorea JG
    Am J Trop Med Hyg; 1995 May; 52(5):435-7. PubMed ID: 7771610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
    J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat.
    Miranda ES; Miekeley N; De-Carvalho RR; Paumgartten FJ
    Reprod Toxicol; 2006 Apr; 21(3):292-300. PubMed ID: 16271447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime).
    Roberts WL; McMurray WJ; Rainey PM
    Antimicrob Agents Chemother; 1998 May; 42(5):1076-82. PubMed ID: 9593130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speciation of antimony in injectable drugs used for leishmaniasis treatment (Glucantime®) by HPLC-ICP-MS and DPP.
    Séby F; Gleyzes C; Grosso O; Plau B; Donard OF
    Anal Bioanal Chem; 2012 Dec; 404(10):2939-48. PubMed ID: 23052871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subacute toxicity of pentavalent antimony compounds in rats.
    alKhawajah A; Larbi EB; Jain S; al-Gindan Y; Abahussain A
    Hum Exp Toxicol; 1992 Jul; 11(4):283-8. PubMed ID: 1354978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Speciation of antimony (III) and antimony (V) using hydride generation for meglumine antimoniate pharmaceutical formulations quality control.
    Cabral LM; Juliano VN; Dias LR; Dornelas CB; Rodrigues CR; Villardi M; Castro HC; Santos TC
    Mem Inst Oswaldo Cruz; 2008 Mar; 103(2):130-7. PubMed ID: 18425264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.
    Shaked-Mishan P; Ulrich N; Ephros M; Zilberstein D
    J Biol Chem; 2001 Feb; 276(6):3971-6. PubMed ID: 11110784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione.
    Ferreira Cdos S; Martins PS; Demicheli C; Brochu C; Ouellette M; Frézard F
    Biometals; 2003 Sep; 16(3):441-6. PubMed ID: 12680707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of action assessment of the genotoxic properties of antimony and its compounds evaluated in the ToxTracker assay.
    Boreiko CJ; Hendriks G; Derr R; Huppert M; Rossman TG
    Mutat Res Genet Toxicol Environ Mutagen; 2021 May; 865():503333. PubMed ID: 33865539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
    de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
    Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speciation of Sb(III) and Sb(V) in meglumine antimoniate pharmaceutical formulations by PSA using carbon nanotube electrode.
    Santos VS; Santos Wde J; Kubota LT; Tarley CR
    J Pharm Biomed Anal; 2009 Sep; 50(2):151-7. PubMed ID: 19423263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.
    Lugo de Yarbuh A; Añez N; Petit de Peña Y; Burguera JL; Burguera M
    Ann Trop Med Parasitol; 1994 Feb; 88(1):37-41. PubMed ID: 8192513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach.
    Salaün P; Frézard F
    Anal Bioanal Chem; 2013 Jun; 405(15):5201-14. PubMed ID: 23612869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-fibrotic effect of 6-bromo-indirubin-3'-oxime (6-BIO) via regulation of activator protein-1 (AP-1) and specificity protein-1 (SP-1) transcription factors in kidney cells.
    Park JS; Jung IA; Choi HS; Kim DH; Choi HI; Bae EH; Ma SK; Kim SW
    Biomed Pharmacother; 2022 Jan; 145():112402. PubMed ID: 34773763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.